To discuss clinical values of the combined analysis on serological patterns, virus DNA titer and pre-S1 antigen for hepatitis B.

Serum samples from 339 patients with chemical luminescent immunoassay (CLIA) positive results were used in the study. The level of serum HBV-DNA was detected by fluorescent quantitative polymerase chain reaction (FQ-PCR). Pre-S1Ag was detected by ELISA.

There was no significant differences in pre-S1 Ag or HBV-DNA with different serological patterns of hepatitis B (P>0.05). The HBV-DNA positive rate of the HBsAg, HBeAg and Anti-HBc positive group was 93.1% while the pre-S1Ag positive rate was 86.1%. The HBV-DNA positive rate of the HBsAg, HBeAb, anti-HBc positive group was 45.9% and the Pre-S1Ag positive rate was 69.2%. The HBV-DNA positive rate of the HBsAg, anti-HBc positive groups was 61.0%. The Pre-S1Ag positive rate was 72.9%. The HBV-DNA and Pre-S1Ag positive rate of the HBsAg, HBeAg positive groups were 100%. The HBV-DNA and Pre-S1Ag positive rates were 87.3% and 93.7% in HBeAg positive samples, respectively. There were statistically significant differences in results of HBV-DNA or pre-S1 Ag(P<0.05).

Combined detection on serological patterns, virus DNA titer and pre-S1 antigen for hepatitis B have important clinical values in correct identification of the HBV infection and replication status. It provides reliable evidences for the selection of methods intreatment and observation of clinical efficacy.

Hepatitis B; Serological marker; Hepatitis B viral DNA; Pre-S1 antigen